Haemophilia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Men, women, and children of any age or ethnic background may be eligible
- You must have severe haemophilia A, meaning your body produces very little or none of a blood-clotting protein called Factor VIII
- Your doctor must have already decided to prescribe an Octapharma Factor VIII treatment before you join the study
- You have either never been treated with Factor VIII products before, OR you have had fewer than 5 treatment sessions with Factor VIII products (with full records available and no history of developing an inhibitor), OR you developed an inhibitor (a resistance to the treatment) while using an Octapharma Factor VIII product and are continuing that same Octapharma treatment
- You (or your parent or legal guardian) must be willing to give written, informed consent before taking part
Who may not be able to join:
- You have a blood-clotting disorder other than haemophilia A
- You are currently taking any medication that suppresses your immune system throughout your whole body
- You are already taking part in another clinical trial that involves a treatment or intervention during the period being studied
- You are already enrolled in another observational (non-interventional) study run by Octapharma
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Sigurd Knaub, PhD, Octapharma
Phone: +41 79 585 90 42
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Annualised rate of breakthrough bleeds to assess efficacy in prophylactic treatment; Incidence of Adverse Drug Reactions (ADRs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.